Loading stock data…
$5.51-0.06 (-0.99%)
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
BioAge Labs, Inc. in the Healthcare sector is trading at $5.51 with a market capitalization of $375M. Wall Street consensus targets $32.56 (9 analysts), implying a +490.3% move over the next 12 months. The stock is currently near its 52-week low of $5.04, remaining 66.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.45M↓ | $2.77M↓ | $3.08M↑ | $2.05M↓ | $2.41M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.33M↓ | -$25.38M↑ | -$28.42M↓ | -$23.14M↑ | -$24.77M |
| Net Income | -$26.10M↓ | -$22.25M↑ | -$25.94M↓ | -$20.17M↑ | -$21.56M |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights...